# Increased distribution of ownership in Boule Diagnostics completed

A number of Swedish private investors have acquired a total of 260,000 shares in Boule Diagnostics, equivalent to 5.5 percent of the company's capital and votes. The increased distribution of ownership is part of Boule Diagnostics' ambition to create conditions for increased liquidity in trading the company's share.

"It is gratifying that there was great interest in the now completed distribution of ownership. This is a first step towards greater liquidity in trading the Boule Diagnostics share, which will continue to be of importance for us," said Ernst Westman, President and CEO of Boule Diagnostics AB.

The sale was carried out as planned, from September 24 through October 4, 2012, with asset allocation October 5, 2012. After completion of the above transaction, the sellers reduce their total holding of 806,506 shares, representing 17.1 percent of the company's shares, to 546,506 shares, representing 11.6 per cent.

**For more information, please contact:**
Ernst Westman, President and CEO, Boule Diagnostics AB, phone +46 708 60 88 63

The information disclosed in this press release is such that Boule Diagnostics AB is required to make this information public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for publication on October 8, 2012 at 08.00 am (CET).

**TO THE EDITORS**
**About Boule Diagnostics AB**
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary haematology. The group is comprised of operating subsidiaries in Sweden, the US and China. Boule Diagnostics' share is, since 2011, traded on NASDAQ OMX Nordic. www.boule.se